Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $124.20 million. The enterprise value is $114.01 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 45.66 million shares outstanding. The number of shares has increased by 26.34% in one year.
| Current Share Class | 45.66M |
| Shares Outstanding | 45.66M |
| Shares Change (YoY) | +26.34% |
| Shares Change (QoQ) | +7.97% |
| Owned by Insiders (%) | 1.97% |
| Owned by Institutions (%) | 8.43% |
| Float | 28.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 750.97 |
| Forward PS | n/a |
| PB Ratio | 6.14 |
| P/TBV Ratio | 7.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 686.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.47, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.47 |
| Quick Ratio | 5.89 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.22% and return on invested capital (ROIC) is -50.28%.
| Return on Equity (ROE) | -82.22% |
| Return on Assets (ROA) | -44.56% |
| Return on Invested Capital (ROIC) | -50.28% |
| Return on Capital Employed (ROCE) | -59.41% |
| Revenue Per Employee | $8,300 |
| Profits Per Employee | -$530,100 |
| Employee Count | 20 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Entera Bio has paid $14,000 in taxes.
| Income Tax | 14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +44.71% in the last 52 weeks. The beta is 1.68, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | +44.71% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 2.03 |
| Relative Strength Index (RSI) | 66.97 |
| Average Volume (20 Days) | 294,963 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Entera Bio had revenue of $166,000 and -$10.60 million in losses. Loss per share was -$0.25.
| Revenue | 166,000 |
| Gross Profit | n/a |
| Operating Income | -10.59M |
| Pretax Income | -10.59M |
| Net Income | -10.60M |
| EBITDA | -10.55M |
| EBIT | -10.59M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $10.86 million in cash and $203,000 in debt, giving a net cash position of $10.66 million or $0.23 per share.
| Cash & Cash Equivalents | 10.86M |
| Total Debt | 203,000 |
| Net Cash | 10.66M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 17.26M |
| Book Value Per Share | 0.44 |
| Working Capital | 17.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.66 million and capital expenditures -$40,000, giving a free cash flow of -$6.70 million.
| Operating Cash Flow | -6.66M |
| Capital Expenditures | -40,000 |
| Free Cash Flow | -6.70M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -6,378.92% |
| Pretax Margin | -6,378.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.34% |
| Shareholder Yield | -26.34% |
| Earnings Yield | -8.50% |
| FCF Yield | -5.37% |
Analyst Forecast
The average price target for Entera Bio is $10.00, which is 267.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 267.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Entera Bio has an Altman Z-Score of 9.77 and a Piotroski F-Score of 3.
| Altman Z-Score | 9.77 |
| Piotroski F-Score | 3 |
